메뉴 건너뛰기




Volumn 142, Issue 1, 2012, Pages

Diagnosis and treatment of diffuse large B-cell lymphoma

Author keywords

Chemotherapy; DLBCL; First line treatment; Follow up; Maintenance treatment; Relapsed refractory disease; Rituximab; Staging

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

EID: 84856805625     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13511     Document Type: Review
Times cited : (26)

References (124)
  • 1
    • 79955835059 scopus 로고    scopus 로고
    • Pathogenesis of Non-Hodgkin's Lymphoma
    • Nogai H, Dorken B, Lenz G. Pathogenesis of Non-Hodgkin's Lymphoma. J Clin Oncol. 2011;29:1803-11.
    • (2011) J Clin Oncol , vol.29 , pp. 1803-1811
    • Nogai, H.1    Dorken, B.2    Lenz, G.3
  • 3
    • 79955961315 scopus 로고    scopus 로고
    • The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications
    • Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019-32.
    • (2011) Blood , vol.117 , pp. 5019-5032
    • Campo, E.1    Swerdlow, S.H.2    Harris, N.L.3
  • 4
    • 27744600585 scopus 로고    scopus 로고
    • WHO non-Hodgkin's lymphoma classification by criterion-based report review followed by targeted pathology review: An effective strategy for epidemiology studies
    • DOI 10.1158/1055-9965.EPI-05-0358
    • Turner JJ, Hughes AM, Kricker A, et al. WHO non-Hodgkin's lymphoma classification by criterion-based report review followed by targeted pathology review: an effective strategy for epidemiology studies. Cancer Epidemiol Biomarkers Prev. 2005;14:2213-9. (Pubitemid 41603270)
    • (2005) Cancer Epidemiology Biomarkers and Prevention , vol.14 , Issue.9 , pp. 2213-2219
    • Turner, J.J.1    Hughes, A.M.2    Kricker, A.3    Milliken, S.4    Grulich, A.5    Kaldor, J.6    Armstrong, B.7
  • 5
    • 78649742465 scopus 로고    scopus 로고
    • Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
    • Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116:4916-25.
    • (2010) Blood , vol.116 , pp. 4916-4925
    • Ott, G.1    Ziepert, M.2    Klapper, W.3
  • 6
    • 67849112968 scopus 로고    scopus 로고
    • Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms
    • Adams H, Liebisch P, Schmid P, et al. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms. Appl Immunohistochem Mol Morphol. 2009;17:96-101.
    • (2009) Appl Immunohistochem Mol Morphol , vol.17 , pp. 96-101
    • Adams, H.1    Liebisch, P.2    Schmid, P.3
  • 7
    • 76349113374 scopus 로고    scopus 로고
    • Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores
    • Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010;51:199-212.
    • (2010) Leuk Lymphoma , vol.51 , pp. 199-212
    • Tzankov, A.1    Zlobec, I.2    Went, P.3
  • 9
    • 77951010885 scopus 로고    scopus 로고
    • Aggressive lymphomas
    • Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417-29.
    • (2010) N Engl J Med , vol.362 , pp. 1417-1429
    • Lenz, G.1    Staudt, L.M.2
  • 10
    • 77954752069 scopus 로고    scopus 로고
    • Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
    • Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-5.
    • (2010) J Clin Oncol , vol.28 , pp. 3360-3365
    • Barrans, S.1    Crouch, S.2    Smith, A.3
  • 11
    • 68149165799 scopus 로고    scopus 로고
    • Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment
    • Obermann EC, Csato M, Dirnhofer S, et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol. 2009;62:754-56.
    • (2009) J Clin Pathol , vol.62 , pp. 754-756
    • Obermann, E.C.1    Csato, M.2    Dirnhofer, S.3
  • 12
    • 70449589073 scopus 로고    scopus 로고
    • MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    • Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533-7.
    • (2009) Blood , vol.114 , pp. 3533-3537
    • Savage, K.J.1    Johnson, N.A.2    Ben-Neriah, S.3
  • 13
    • 45749152667 scopus 로고    scopus 로고
    • Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    • Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717-24.
    • (2008) J Clin Oncol , vol.26 , pp. 2717-2724
    • Wilson, W.H.1    Dunleavy, K.2    Pittaluga, S.3
  • 14
    • 67650398258 scopus 로고    scopus 로고
    • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    • Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069-76.
    • (2009) Blood , vol.113 , pp. 6069-6076
    • Dunleavy, K.1    Pittaluga, S.2    Czuczman, M.S.3
  • 15
    • 53749093794 scopus 로고    scopus 로고
    • Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
    • Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26:4587-94.
    • (2008) J Clin Oncol , vol.26 , pp. 4587-4594
    • Fu, K.1    Weisenburger, D.D.2    Choi, W.W.3
  • 16
    • 79955944673 scopus 로고    scopus 로고
    • Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
    • Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117:4836-43.
    • (2011) Blood , vol.117 , pp. 4836-4843
    • Gutierrez-Garcia, G.1    Cardesa-Salzmann, T.2    Climent, F.3
  • 17
    • 0027444652 scopus 로고
    • A predictive model for aggressive non-Hodgkin's lymphoma
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project
    • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
    • (1993) N Engl J Med , vol.329 , pp. 987-994
  • 18
    • 0032174930 scopus 로고    scopus 로고
    • Establishing the diagnosis of lymphoma: From initial biopsy to clinical staging
    • Gascoyne RD. Establishing the diagnosis of lymphoma: from initial biopsy to clinical staging. Oncology (Williston Park). 1998;12:11-6. (Pubitemid 128637449)
    • (1998) ONCOLOGY , vol.12 , Issue.10 SUPPL. 8 , pp. 11-16
    • Gascoyne, R.D.1
  • 19
    • 77954356939 scopus 로고    scopus 로고
    • Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v172-v174.
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • Tilly, H.1    Dreyling, M.2
  • 20
    • 78650064032 scopus 로고    scopus 로고
    • Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy
    • Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. 2010;28:5097-100.
    • (2010) J Clin Oncol , vol.28 , pp. 5097-5100
    • Niitsu, N.1    Hagiwara, Y.2    Tanae, K.3
  • 21
    • 78650066026 scopus 로고    scopus 로고
    • How I treat elderly patients with diffuse large B-cell lymphoma
    • Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103-10.
    • (2010) Blood , vol.116 , pp. 5103-5110
    • Pfreundschuh, M.1
  • 22
    • 4143066762 scopus 로고    scopus 로고
    • Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - Do we need contrast-enhanced CT?
    • DOI 10.1148/radiol.2323030985
    • Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology. 2004;232:823-9. (Pubitemid 39100269)
    • (2004) Radiology , vol.232 , Issue.3 , pp. 823-829
    • Schaefer, N.G.1    Hany, T.F.2    Taverna, C.3    Seifert, B.4    Stumpe, K.D.M.5    Von Schulthess, G.K.6    Goerres, G.W.7
  • 24
    • 79955833418 scopus 로고    scopus 로고
    • Role of functional imaging in the management of lymphoma
    • Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844-54.
    • (2011) J Clin Oncol , vol.29 , pp. 1844-1854
    • Cheson, B.D.1
  • 25
    • 69949096414 scopus 로고    scopus 로고
    • Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with Diffuse Large B-Cell Lymphoma (DLCL)
    • ASH Annual Meeting Abstracts Abstract 371
    • Cashen A, Dehdashti F, Luo J, et al. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with Diffuse Large B-Cell Lymphoma (DLCL). Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 371.
    • (2008) Blood , vol.112
    • Cashen, A.1    Dehdashti, F.2    Luo, J.3
  • 26
    • 77956273523 scopus 로고    scopus 로고
    • Interim 18f[FDG] positron emission tomography in patients with diffuse large B-cell lymphoma
    • ASH Annual Meeting Abstracts Abstract 3609
    • Gigli F, Nassi L, Negri M, et al. Interim 18f[FDG] positron emission tomography in patients with diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 3609.
    • (2008) Blood , vol.112
    • Gigli, F.1    Nassi, L.2    Negri, M.3
  • 27
  • 28
    • 24044553298 scopus 로고    scopus 로고
    • FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
    • DOI 10.1093/annonc/mdi272
    • Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-23. (Pubitemid 41222425)
    • (2005) Annals of Oncology , vol.16 , Issue.9 , pp. 1514-1523
    • Mikhaeel, N.G.1    Hutchings, M.2    Fields, P.A.3    O'Doherty, M.J.4    Timothy, A.R.5
  • 29
    • 79951909502 scopus 로고    scopus 로고
    • Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) failed to predict different outcome in Diffuse Large B-Cell Lymphoma (DLBCL) patients treated with rituximab-CHOP
    • ASH Annual Meeting Abstracts Abstract 99
    • Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) failed to predict different outcome in Diffuse Large B-Cell Lymphoma (DLBCL) patients treated with rituximab-CHOP. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 99.
    • (2009) Blood , vol.114
    • Pregno, P.1    Chiappella, A.2    Bello, M.3
  • 30
    • 79951925609 scopus 로고    scopus 로고
    • Early 18fluorodeoxyglucose PET scan as a prognostic tool in diffuse large B-cell lymphoma patients treated with an anthracycline-based chemotherapy plus rituximab
    • ASH Annual Meeting Abstracts Abstract 98
    • Safar V, Dupuis J, Jardin F, et al. Early 18fluorodeoxyglucose PET scan as a prognostic tool in diffuse large B-cell lymphoma patients treated with an anthracycline-based chemotherapy plus rituximab. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 98.
    • (2009) Blood , vol.114
    • Safar, V.1    Dupuis, J.2    Jardin, F.3
  • 31
    • 0036739436 scopus 로고    scopus 로고
    • Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    • Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-63.
    • (2002) Ann Oncol , vol.13 , pp. 1356-1363
    • Spaepen, K.1    Stroobants, S.2    Dupont, P.3
  • 32
    • 84889724388 scopus 로고    scopus 로고
    • First results of a prospective evaluation of interim PET in patients with DLBCL treated with R-CHOP-14 (SAKK 38/07)
    • Mamot C, Klingbiel D, Renner C, et al. First results of a prospective evaluation of interim PET in patients with DLBCL treated with R-CHOP-14 (SAKK 38/07). Ann Oncol. 2011;22(Suppl 4):218.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4 , pp. 218
    • Mamot, C.1    Klingbiel, D.2    Renner, C.3
  • 34
    • 48149110535 scopus 로고    scopus 로고
    • New response criteria for lymphomas in clinical trials
    • Cheson BD. New response criteria for lymphomas in clinical trials. Ann Oncol. 2008;19(Suppl 4):iv35-iv38.
    • (2008) Ann Oncol , vol.19 , Issue.SUPPL. 4
    • Cheson, B.D.1
  • 35
    • 84856776103 scopus 로고    scopus 로고
    • FDG-PET scan guided consolidative radiation therapy optimizes outcome in patients with advanced-stage diffuse large B-cell lymphoma (DLBCL) with residual abnormalities on CT Scan Following R-CHOP
    • ASH Annual Meeting Abstracts Abstract 854
    • Sehn L, Hoskins P, Klasa R, et al. FDG-PET scan guided consolidative radiation therapy optimizes outcome in patients with advanced-stage diffuse large B-cell lymphoma (DLBCL) with residual abnormalities on CT Scan Following R-CHOP. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 854.
    • (2010) Blood , vol.116
    • Sehn, L.1    Hoskins, P.2    Klasa, R.3
  • 37
    • 77958498166 scopus 로고    scopus 로고
    • Front-line management of diffuse large B cell lymphoma
    • Cabanillas F. Front-line management of diffuse large B cell lymphoma. Curr Opin Oncol. 2010;22:642-5.
    • (2010) Curr Opin Oncol , vol.22 , pp. 642-645
    • Cabanillas, F.1
  • 42
    • 27244445488 scopus 로고    scopus 로고
    • State-of-the-art therapeutics: Diffuse large B-cell lymphoma
    • DOI 10.1200/JCO.2005.05.015
    • Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6387-93. (Pubitemid 46218851)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.26 , pp. 6387-6393
    • Coiffier, B.1
  • 45
    • 77957200763 scopus 로고    scopus 로고
    • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte
    • Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-5.
    • (2010) Blood , vol.116 , pp. 2040-2045
    • Coiffier, B.1    Thieblemont, C.2    Van Den Neste, E.3
  • 47
    • 38549147027 scopus 로고    scopus 로고
    • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
    • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16.
    • (2008) Lancet Oncol , vol.9 , pp. 105-116
    • Pfreundschuh, M.1    Schubert, J.2    Ziepert, M.3
  • 49
    • 70349647262 scopus 로고    scopus 로고
    • A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma
    • Meeting Abstracts Abstract 8506
    • Cunningham D, Smith P, Mouncey W, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol. (Meeting Abstracts). 2009;27:Abstract 8506.
    • (2009) J Clin Oncol , vol.27
    • Cunningham, D.1    Smith, P.2    Mouncey, W.3
  • 50
    • 80054750428 scopus 로고    scopus 로고
    • R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma
    • meeting abstracts abstract 8000
    • Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol (meeting abstracts). 2011;29:abstract 8000.
    • (2011) J Clin Oncol , pp. 29
    • Cunningham, D.1    Smith, P.2    Mouncey, P.3
  • 51
    • 82755184062 scopus 로고    scopus 로고
    • R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the second interim analysis of the LNH03-6B GELA study
    • Abstract 106
    • Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the second interim analysis of the LNH03-6B GELA study. Ann Oncol. 2011;22(Suppl. 4):Abstract 106.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Delarue, R.1    Tilly, H.2    Salles, G.3
  • 52
    • 58649108514 scopus 로고    scopus 로고
    • Dose-dense rituximab improves outcome of elderly patients with poor-prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    • ASH annual meeting abstracts abstract 789
    • Pfreundschuh M, Zeynalova S, Poeschel V, et al. Dose-dense rituximab improves outcome of elderly patients with poor-prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (ASH annual meeting abstracts). 2007;110:abstract 789.
    • (2007) Blood , vol.110
    • Pfreundschuh, M.1    Zeynalova, S.2    Poeschel, V.3
  • 53
    • 79952664845 scopus 로고    scopus 로고
    • Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results from 4 prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL)
    • ASH Annual Meeting Abstracts Abstract 3715
    • Pfreundschuh M, Murawski N, Zeynalova S, et al. Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results from 4 prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL). Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 3715.
    • (2009) Blood , vol.114
    • Pfreundschuh, M.1    Murawski, N.2    Zeynalova, S.3
  • 54
    • 79955468338 scopus 로고    scopus 로고
    • Hope for very elderly patients with diffuse large B-cell lymphoma
    • Ribera JM. Hope for very elderly patients with diffuse large B-cell lymphoma. Lancet Oncol. 2011;12:412-3.
    • (2011) Lancet Oncol , vol.12 , pp. 412-413
    • Ribera, J.M.1
  • 55
    • 25444468844 scopus 로고    scopus 로고
    • Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old
    • Italiano A, Jardin F, Peyrade F, et al. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica. 2005;90:1281-3. (Pubitemid 41375292)
    • (2005) Haematologica , vol.90 , Issue.9 , pp. 1281-1283
    • Italiano, A.1    Jardin, F.2    Peyrade, F.3    Saudes, L.4    Tilly, H.5    Thyss, A.6
  • 56
    • 79955473473 scopus 로고    scopus 로고
    • Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial
    • Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460-8.
    • (2011) Lancet Oncol , vol.12 , pp. 460-468
    • Peyrade, F.1    Jardin, F.2    Thieblemont, C.3
  • 57
    • 79955485192 scopus 로고    scopus 로고
    • Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
    • Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839-44.
    • (2011) Ann Oncol , vol.22 , pp. 1839-1844
    • Weidmann, E.1    Neumann, A.2    Fauth, F.3
  • 58
    • 78649391451 scopus 로고    scopus 로고
    • Improving outcomes for patients with diffuse large B-cell lymphoma
    • Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393-408.
    • (2010) CA Cancer J Clin , vol.60 , pp. 393-408
    • Flowers, C.R.1    Sinha, R.2    Vose, J.M.3
  • 59
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91.
    • (2006) Lancet Oncol , vol.7 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 60
    • 80053384016 scopus 로고    scopus 로고
    • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-21.
    • (2011) Lancet Oncol , vol.12 , pp. 1013-1021
    • Pfreundschuh, M.1    Kuhnt, E.2    Trumper, L.3
  • 63
    • 82255186682 scopus 로고    scopus 로고
    • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
    • Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858-67.
    • (2011) Lancet , vol.378 , pp. 1858-1867
    • Recher, C.1    Coiffier, B.2    Haioun, C.3
  • 64
    • 33645983193 scopus 로고    scopus 로고
    • Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large Bcell lymphoma: A phase II study of feasibility and toxicity
    • Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large Bcell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496-502.
    • (2006) Haematologica , vol.91 , pp. 496-502
    • Brusamolino, E.1    Rusconi, C.2    Montalbetti, L.3
  • 67
    • 80053386630 scopus 로고    scopus 로고
    • R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group
    • Epub ahead of print
    • Gang AO, Strom C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2011; Epub ahead of print.
    • (2011) Ann Oncol
    • Gang, A.O.1    Strom, C.2    Pedersen, M.3
  • 68
    • 84855281681 scopus 로고    scopus 로고
    • Myc + agressive B-cell lymphomas: Novel therapy of untreated Burkitt lymphoma (BL) and Myc+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R
    • Dunleavy K, Pittaluga S, Wayne S, et al. Myc + agressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and Myc+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol. 2011;22(Suppl 4):071.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4 , pp. 071
    • Dunleavy, K.1    Pittaluga, S.2    Wayne, S.3
  • 69
    • 23444453888 scopus 로고    scopus 로고
    • Best treatment of aggressive non-Hodgkin's lymphoma: A French perspective
    • Williston Park
    • Coiffier B, Reyes F. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. Oncology. (Williston Park). 2005;19:7-15.
    • (2005) Oncology , vol.19 , pp. 7-15
    • Coiffier, B.1    Reyes, F.2
  • 70
    • 79961096440 scopus 로고    scopus 로고
    • Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA
    • Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96:1136-43.
    • (2011) Haematologica , vol.96 , pp. 1136-1143
    • Fitoussi, O.1    Belhadj, K.2    Mounier, N.3
  • 71
    • 44949229297 scopus 로고    scopus 로고
    • High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults
    • CD004024
    • Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. 2008;1:CD004024.
    • (2008) Cochrane Database Syst Rev , vol.1
    • Greb, A.1    Bohlius, J.2    Schiefer, D.3
  • 72
    • 80054723216 scopus 로고    scopus 로고
    • First-line rituximab (R) highdose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial
    • Meeting Abstracts Abstract 8003
    • Le Gouill S, Milpied N, Lamy T, et al. First-line rituximab (R) highdose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol (Meeting Abstracts). 2011;29:Abstract 8003.
    • (2011) J Clin Oncol , vol.29
    • Le Gouill, S.1    Milpied, N.2    Lamy, T.3
  • 73
    • 80053385621 scopus 로고    scopus 로고
    • Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL)
    • Meeting Abstracts Abstract 8002
    • Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). J Clin Oncol (Meeting Abstracts). 2011;29:Abstract 8002.
    • (2011) J Clin Oncol , vol.29
    • Schmitz, N.1    Nickelsen, M.2    Ziepert, M.3
  • 74
    • 84889716721 scopus 로고    scopus 로고
    • A randomized multicentre phase III study for first line treatment of young patients with high risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): Rituximab (R) plus dose-dense chemotherapy CHOP14/MegaCHOP14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT)
    • Abstract 072
    • Vitolo U, Chiappella A, Brusamolino E, et al. A randomized multicentre phase III study for first line treatment of young patients with high risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): Rituximab (R) plus dose-dense chemotherapy CHOP14/MegaCHOP14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Ann Oncol. 2011;22(Supplement 4):Abstract 072.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Vitolo, U.1    Chiappella, A.2    Brusamolino, E.3
  • 75
    • 80052980811 scopus 로고    scopus 로고
    • Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL)
    • Meeting Abstracts Abstract 8001
    • Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol (Meeting Abstracts). 2011;29:Abstract 8001.
    • (2011) J Clin Oncol , vol.29
    • Stiff, P.J.1    Unger, J.M.2    Cook, J.3
  • 76
    • 0027479127 scopus 로고
    • Treatment of non-Hodgkin's lymphoma
    • DOI 10.1056/NEJM199304083281409
    • Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1023-30. (Pubitemid 23095688)
    • (1993) New England Journal of Medicine , vol.328 , Issue.14 , pp. 1023-1030
    • Armitage, J.O.1
  • 78
    • 0003242248 scopus 로고    scopus 로고
    • CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial
    • ASH Annual Meeting Abstracts
    • Miller TP, LeBlanc M, Spier CM, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood (ASH Annual Meeting Abstracts). 2001;98:724a.
    • (2001) Blood , vol.98
    • Miller, T.P.1    LeBlanc, M.2    Spier, C.M.3
  • 79
    • 44249092120 scopus 로고    scopus 로고
    • Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
    • Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258-63.
    • (2008) J Clin Oncol , vol.26 , pp. 2258-2263
    • Persky, D.O.1    Unger, J.M.2    Spier, C.M.3
  • 81
    • 84856799681 scopus 로고    scopus 로고
    • Treatment of limited-stage DLBCL can be effectively tailored using a PET-based approach
    • Abstract 028
    • Sehn L, Savage KJ, Hoskins P, et al. Treatment of limited-stage DLBCL can be effectively tailored using a PET-based approach. Ann Oncol. 2011;22(Suppl. 4):Abstract 028.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Sehn, L.1    Savage, K.J.2    Hoskins, P.3
  • 84
    • 69549135986 scopus 로고    scopus 로고
    • Localized large cell lymphoma: Is there any need for radiation therapy?
    • Persky DO, Miller TP. Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol. 2009;21:401-6.
    • (2009) Curr Opin Oncol , vol.21 , pp. 401-406
    • Persky, D.O.1    Miller, T.P.2
  • 85
    • 42649113874 scopus 로고    scopus 로고
    • Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study
    • Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435-44.
    • (2008) Lancet Oncol , vol.9 , pp. 435-444
    • Pfreundschuh, M.1    Ho, A.D.2    Cavallin-Stahl, E.3
  • 86
    • 77949446062 scopus 로고    scopus 로고
    • The role of radiotherapy to bulky disease in the rituximab era: Results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL
    • ASH Annual Meeting Abstracts Abstract 584
    • Pfreundschuh M, Ziepert M, Reiser M, et al. The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 584.
    • (2008) Blood , vol.112
    • Pfreundschuh, M.1    Ziepert, M.2    Reiser, M.3
  • 87
    • 75349111310 scopus 로고    scopus 로고
    • Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: In pursuit of a complete response
    • Gisselbrecht C, Vose J, Nademanee A, et al. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist. 2009;14(Suppl 2):41-51.
    • (2009) Oncologist , vol.14 , Issue.SUPPL. 2 , pp. 41-51
    • Gisselbrecht, C.1    Vose, J.2    Nademanee, A.3
  • 88
    • 79952006855 scopus 로고    scopus 로고
    • Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era
    • Mounier N, Gisselbrecht C. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Curr Opin Oncol. 2011;23:209-13.
    • (2011) Curr Opin Oncol , vol.23 , pp. 209-213
    • Mounier, N.1    Gisselbrecht, C.2
  • 90
    • 0028790440 scopus 로고
    • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
    • Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-5.
    • (1995) N Engl J Med , vol.333 , pp. 1540-1545
    • Philip, T.1    Guglielmi, C.2    Hagenbeek, A.3
  • 91
    • 77954682208 scopus 로고    scopus 로고
    • ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma
    • Aviles A, Neri N, Huerta-Guzman J, et al. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:125-8.
    • (2010) Clin Lymphoma Myeloma Leuk , vol.10 , pp. 125-128
    • Aviles, A.1    Neri, N.2    Huerta-Guzman, J.3
  • 92
    • 77950103411 scopus 로고    scopus 로고
    • Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma
    • Ueda K, Nannya Y, Asai T, et al. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma. J Chemother. 2010;22:54-7.
    • (2010) J Chemother , vol.22 , pp. 54-57
    • Ueda, K.1    Nannya, Y.2    Asai, T.3
  • 93
    • 33845902264 scopus 로고    scopus 로고
    • Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: Results from a prospective observational study
    • DOI 10.1111/j.1365-2141.2006.06438.x
    • Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136:276-85. (Pubitemid 46020755)
    • (2007) British Journal of Haematology , vol.136 , Issue.2 , pp. 276-285
    • Garcia-Suarez, J.1    Banas, H.2    Arribas, I.3    De Miguel, D.4    Pascual, T.5    Burgaleta, C.6
  • 94
    • 0025188051 scopus 로고
    • CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma
    • Chao NJ, Rosenberg SA, and Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood. 1990;76:1293-8. (Pubitemid 20342742)
    • (1990) Blood , vol.76 , Issue.7 , pp. 1293-1298
    • Chao, N.J.1    Rosenberg, S.A.2    Horning, S.J.3
  • 96
    • 76149111943 scopus 로고    scopus 로고
    • High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma
    • Persky DO, Moskowitz CH, Filatov A, et al. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2010;18:35-40.
    • (2010) Appl Immunohistochem Mol Morphol , vol.18 , pp. 35-40
    • Persky, D.O.1    Moskowitz, C.H.2    Filatov, A.3
  • 98
    • 77957965500 scopus 로고    scopus 로고
    • Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
    • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-90.
    • (2010) J Clin Oncol , vol.28 , pp. 4184-4190
    • Gisselbrecht, C.1    Glass, B.2    Mounier, N.3
  • 99
    • 80755143466 scopus 로고    scopus 로고
    • The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study
    • Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079-87.
    • (2011) J Clin Oncol , vol.29 , pp. 4079-4087
    • Thieblemont, C.1    Briere, J.2    Mounier, N.3
  • 100
    • 78049506962 scopus 로고    scopus 로고
    • New drugs for aggressive B-cell and T-cell lymphomas
    • Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010;11:1074-85.
    • (2010) Lancet Oncol , vol.11 , pp. 1074-1085
    • Murawski, N.1    Pfreundschuh, M.2
  • 103
    • 50549098176 scopus 로고    scopus 로고
    • Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma
    • Maloney D. Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant. 2008;42(Suppl 1):S35-S36.
    • (2008) Bone Marrow Transplant , vol.42 , Issue.SUPPL. 1
    • Maloney, D.1
  • 104
    • 58549104567 scopus 로고    scopus 로고
    • Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma
    • Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:426-32.
    • (2009) J Clin Oncol , vol.27 , pp. 426-432
    • Thomson, K.J.1    Morris, E.C.2    Bloor, A.3
  • 105
    • 72649091641 scopus 로고    scopus 로고
    • Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: Report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
    • Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant. 2010;16:78-85.
    • (2010) Biol Blood Marrow Transplant , vol.16 , pp. 78-85
    • Sirvent, A.1    Dhedin, N.2    Michallet, M.3
  • 106
    • 55749099667 scopus 로고    scopus 로고
    • Management of relapsed diffuse large B-cell lymphoma
    • Kenkre VP, Smith SM. Management of relapsed diffuse large B-cell lymphoma. Curr Oncol Rep. 2008;10:393-403.
    • (2008) Curr Oncol Rep , vol.10 , pp. 393-403
    • Kenkre, V.P.1    Smith, S.M.2
  • 108
    • 38049126171 scopus 로고    scopus 로고
    • GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study
    • Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008;80:127-32.
    • (2008) Eur J Haematol , vol.80 , pp. 127-132
    • Lopez, A.1    Gutierrez, A.2    Palacios, A.3
  • 110
    • 0035990837 scopus 로고    scopus 로고
    • Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model
    • Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099-107.
    • (2002) Ann Oncol , vol.13 , pp. 1099-1107
    • Hollender, A.1    Kvaloy, S.2    Nome, O.3
  • 112
    • 19944428085 scopus 로고    scopus 로고
    • High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology
    • DOI 10.1182/blood-2004-05-1982
    • Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496-502. (Pubitemid 40070727)
    • (2005) Blood , vol.105 , Issue.2 , pp. 496-502
    • Hegde, U.1    Filie, A.2    Little, R.F.3    Janik, J.E.4    Grant, N.5    Steinberg, S.M.6    Dunleavy, K.7    Jaffe, E.S.8    Abati, A.9    Stetler-Stevenson, M.10    Wilson, W.H.11
  • 113
    • 65449139164 scopus 로고    scopus 로고
    • CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    • Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113:3896-902.
    • (2009) Blood , vol.113 , pp. 3896-3902
    • Boehme, V.1    Schmitz, N.2    Zeynalova, S.3
  • 114
    • 77957331593 scopus 로고    scopus 로고
    • Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma
    • O'Rourke K, Morris K, Kennedy GA. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283-90.
    • (2010) Cancer , vol.116 , pp. 4283-4290
    • O'Rourke, K.1    Morris, K.2    Kennedy, G.A.3
  • 115
    • 79960239204 scopus 로고    scopus 로고
    • First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial
    • Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766-72.
    • (2011) J Clin Oncol , vol.29 , pp. 2766-2772
    • Vitolo, U.1    Chiappella, A.2    Ferreri, A.J.3
  • 116
    • 67849094665 scopus 로고    scopus 로고
    • Central nervous system disease in hematologic malignancies: Historical perspective and practical applications
    • Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol. 2009;36:S2-S16.
    • (2009) Semin Oncol , vol.36
    • Pui, C.H.1    Thiel, E.2
  • 117
    • 80052026259 scopus 로고    scopus 로고
    • Prevention of central nervous system relapses in diffuse large B-cell lymphoma: Which patients and how?
    • Korfel A. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol. 2011;23:436-40.
    • (2011) Curr Opin Oncol , vol.23 , pp. 436-440
    • Korfel, A.1
  • 118
    • 77953351708 scopus 로고    scopus 로고
    • Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy
    • Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21:1046-52.
    • (2010) Ann Oncol , vol.21 , pp. 1046-1052
    • Villa, D.1    Connors, J.M.2    Shenkier, T.N.3
  • 119
    • 79960283082 scopus 로고    scopus 로고
    • Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre- And post-rituximab
    • Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90:809-18.
    • (2011) Ann Hematol , vol.90 , pp. 809-818
    • Tai, W.M.1    Chung, J.2    Tang, P.L.3
  • 120
    • 33846531961 scopus 로고    scopus 로고
    • Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    • DOI 10.1093/annonc/mdl327
    • Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149-57. (Pubitemid 46152515)
    • (2007) Annals of Oncology , vol.18 , Issue.1 , pp. 149-157
    • Boehme, V.1    Zeynalova, S.2    Kloess, M.3    Loeffler, M.4    Kaiser, U.5    Pfreundschuh, M.6    Schmitz, N.7
  • 121
    • 79952741195 scopus 로고    scopus 로고
    • Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia
    • Saloustros E, Tryfonidis K, Georgoulias V. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother. 2011;12:851-63.
    • (2011) Expert Opin Pharmacother , vol.12 , pp. 851-863
    • Saloustros, E.1    Tryfonidis, K.2    Georgoulias, V.3
  • 123
    • 78650515906 scopus 로고    scopus 로고
    • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    • Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.
    • (2011) Eur J Cancer , vol.47 , pp. 8-32
    • Aapro, M.S.1    Bohlius, J.2    Cameron, D.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.